Gain Therapeutics CFO C. Evan Ballantyne resigns; Gianluca Fuggetta appointed Principal Financial Officer

Gain Therapeutics, Inc.

CFO C. Evan Ballantyne resigns effective March 1, 2024, departing all positions.
Gianluca Fuggetta, current Senior Director, appointed VP of Finance and Principal Financial Officer from March 1.
Company has initiated a search to identify a new Chief Financial Officer.
Fuggetta previously served as Assurance Manager at PwC; joined Gain in July 2022.
No family relationships or arrangements exist in connection with his appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

C. Evan Ballantyne

Chief Financial Officer

GANX · Gain Therapeutics, Inc.

Effective: 2024-03-01
Filed: February 22, 2024, 6:59 PM ET

On February 19, 2024, Gain Therapeutics, Inc. (the “Company”) received notice of the resignation of C. Evan Ballantyne as the Company’s Chief Financial Officer, and all other positions held at the Company, to be effective March 1, 2024.

Appointed

Gianluca Fuggetta

Vice President of Finance, Principal Financial Officer

GANX · Gain Therapeutics, Inc.

Effective: 2024-03-01
Filed: February 22, 2024, 6:59 PM ET

On February 21, 2024, the Board of Directors of the Company appointed Gianluca Fuggetta, the Company’s current Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, as the Company’s Vice President of Finance and to also serve as the Company’s Principal Financial Officer, to be effective March 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

C. Evan Ballantyne resigned as Chief Financial Officer at Gain Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On February 19, 2024, Gain Therapeutics, Inc. (the “Company”) received notice of the resignation of C. Evan Ballantyne as the Company’s Chief Financial Officer, and all other positions held at the Company, to be effective March 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gianluca Fuggetta was appointed as Vice President of Finance, Principal Financial Officer at Gain Therapeutics, Inc..

Action: appointed
Role: Vice President of Finance, Principal Financial Officer

Exact text from the filing

On February 21, 2024, the Board of Directors of the Company appointed Gianluca Fuggetta, the Company’s current Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, as the Company’s Vice President of Finance and to also serve as the Company’s Principal Financial Officer, to be effective March 1, 2024.

View on SEC.gov

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-026302

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.